 - Any other ongoing anti-tumor treatment including chemotherapy, immunotherapy, cytokines, interferons, protease inhibitors or gene therapy administered. The use of of GnRH-agonistantagonists with or without bicalutamide is acceptable with the exception of GnRH-agonist with or without bicalutamide started up to 6 months prior to inclusion 